ImClone Systems : ERBITUX(R) Phase 3 BMS-099 Lung Cancer Study Secondary Endpoint Update: Overall Survival Results Announced

Aug. 29, 2008 - ImClone Systems Incorporated (NASDAQ: IMCL) announced overall survival results from BMS CA225-099 (BMS-099), an open-label Phase 3 study of ERBITUX(R) (cetuximab) in combination with a taxane and carboplatin in the first-line treatment of all histological subtypes of advanced non-small cell lung cancer (NSCLC).

These results pertaining to overall survival, a secondary endpoint, are an update to the previously reported results for progression-free survival (PFS), the study's primary endpoint, which were announced in June 2007. The study did not meet its primary endpoint of PFS, as assessed by an independent radiology review committee (IRRC). Response rate, as assessed by the IRRC, and PFS, as assessed by clinical investigators, were statistically significant and favored the ERBITUX-containing arm... ImClone Systems' Press Release -

ImClone : Significant Data on ERBITUX (cetuximab) and ImClone Pipeline to Be Presented at American Society of Clinical Oncology 2008 Annual Meeting

May 16, 2008 - ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that significant scientific data on ERBITUX(R) (cetuximab) will be presented at the American Society of Clinical Oncology (ASCO) 2008 Annual Meeting taking place May 30 through June 3, 2008 in Chicago...
...

Non-Small Cell Lung Cancer

• A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (PTS) with stage III A/B NSCLC: A report of the 2-year and median survival (MS) for the RTOG 0324 trial. G.R. Blumenschein (#7516)
• A phase II study of pemetrexed, carboplatin and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407 - - Early evaluation of feasibility and toxicity. R. Govindan (#7518)... ImClone Systems' Press Release -
  

ImClone , Expands IMC-A12 Development with Ten New Planned Clinical Trials

Sept. 20, 2007--ImClone Systems Incorporated (NASDAQ: IMCL) announced that the Cancer Therapy Evaluation Program (CTEP) of the Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI), has selected 10 proposals for Phase I/II clinical trials of ImClone Systems' anti-insulin-like growth factor-1 receptor (IGR-IR) monoclonal antibody known as IMC-A12...Both randomized and nonrandomized Phase II trials sponsored by CTEP will explore the clinical activity, pharmacology and biological effects of IMC-A12 as a single agent or combined with other relevant anticancer agents in a wide range of malignancies including breast, lung, pancreas and liver cancers, as well as both adult and pediatric sarcomas... ImClone's Press Release -

ImClone and BMS, ERBITUX ,Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study

Tuesday September 11,, 2007 - ImClone Systems Incorporated (NASDAQ: IMCL) and Bristol-Myers Squibb Company (NYSE: BMY) announced that a Phase III study of ERBITUX® (Cetuximab) in combination with platinum-based chemotherapy (vinorelbine plus cisplatin) met its primary endpoint of increasing overall survival compared with chemotherapy alone in patients with advanced non-small cell lung cancer (NSCLC)...
Bristol-Myers Squibb Company's Press Release -
ImClone Systems Incorporated's Press Release -